149 results match your criteria keynote speaker

Trends in Number of Women Speakers at the American Head and Neck Society Meetings, 2007-2019.

JAMA Otolaryngol Head Neck Surg 2021 Jul 24. Epub 2021 Jul 24.

Department of Otolaryngology-Head and Neck Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio.

Importance: The number of female speakers at American Head and Neck Society (AHNS) conferences should ideally be consistent with the number of women entering head and neck surgery fellowships to ensure gender equity in the field. Yet the presence of women speakers at the annual AHNS meetings, which is specific to the field of head and neck cancer, endocrine and microvascular reconstructive surgery, has yet to be studied.

Objective: To determine whether the proportion of female speakers at the AHNS has increased in a manner consistent with the numbers of women entering fellowships since 2007. Read More

View Article and Full-Text PDF

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.

Ann Oncol 2021 Aug 1;32(8):994-1004. Epub 2021 Jul 1.

Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, USA.

Background: In the phase III IMpassion130 trial, combining atezolizumab with first-line nanoparticle albumin-bound-paclitaxel for advanced triple-negative breast cancer (aTNBC) showed a statistically significant progression-free survival (PFS) benefit in the intention-to-treat (ITT) and programmed death-ligand 1 (PD-L1)-positive populations, and a clinically meaningful overall survival (OS) effect in PD-L1-positive aTNBC. The phase III KEYNOTE-355 trial adding pembrolizumab to chemotherapy for aTNBC showed similar PFS effects. IMpassion131 evaluated first-line atezolizumab-paclitaxel in aTNBC. Read More

View Article and Full-Text PDF

Disparity in Gender Representation of Speakers at National Emergency Medical Services Conferences: A Current Assessment and Proposed Path Forward.

Prehosp Disaster Med 2021 Aug 30;36(4):445-449. Epub 2021 Jun 30.

Department of Emergency Medicine, Stony Brook University Hospital, Stony Brook, New YorkUSA.

Introduction: Gender disparities between Emergency Medicine physicians with regards to salary, promotion, and scholarly recognition as national conference speakers have been well-documented. However, little is known if similar gender disparities impact their out-of-hospital Emergency Medical Services (EMS) colleagues. Although there have been improvements in the ratio of women entering the EMS workforce, gender representation has improved at a slower rate for paramedics compared to emergency medical technicians (EMTs). Read More

View Article and Full-Text PDF

Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey.

ESMO Open 2021 06 25;6(3):100131. Epub 2021 May 25.

Thoracic Oncology Unit, Medical Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Background: European Society for Medical Oncology Women for Oncology (ESMO W4O) research has previously shown under-representation of female oncologists in leadership roles. As early reports suggested disproportionate effects of the COVID-19 pandemic on women, the ESMO W4O Committee initiated a study on the impact of the pandemic on the lives of female and male oncologists.

Methods: A questionnaire was sent to ESMO members and put on the ESMO website between 8 June 2020 and 2 July 2020. Read More

View Article and Full-Text PDF

TMB cut-offs fail to predict benefit of PD-1 blockade in gastroesophageal adenocarcinoma in KEYNOTE-061.

Ann Oncol 2021 Jun 15. Epub 2021 Jun 15.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA. Electronic address:

View Article and Full-Text PDF

Should We Re-think Regulations and Standards for Lighting at Workplaces? A Practice Review on Existing Lighting Recommendations.

Front Psychiatry 2021 13;12:652161. Epub 2021 May 13.

Centre for Chronobiology, Psychiatric Hospital of the University of Basel, Basel, Switzerland.

Nowadays lighting projects often include temporal variations of the light, both spectrally and in terms of intensity to consider non-visual effects of light on people. However, as of today there are no specific regulations. Compliance with common lighting standards that address visual aspects of light, often means that only little non-visually effective light reaches the eye. Read More

View Article and Full-Text PDF

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.

Lancet Oncol 2021 07 26;22(7):931-945. Epub 2021 May 26.

University of Michigan Health System, Ann Arbor, MI, USA.

Background: PD-1 and PD-L1 inhibitors are active in metastatic urothelial carcinoma, but positive randomised data supporting their use as a first-line treatment are lacking. In this study we assessed outcomes with first-line pembrolizumab alone or combined with chemotherapy versus chemotherapy for patients with previously untreated advanced urothelial carcinoma.

Methods: KEYNOTE-361 is a randomised, open-label, phase 3 trial of patients aged at least 18 years, with untreated, locally advanced, unresectable, or metastatic urothelial carcinoma, with an Eastern Cooperative Oncology Group performance status of up to 2. Read More

View Article and Full-Text PDF

Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189.

Ann Oncol 2021 07 22;32(7):881-895. Epub 2021 Apr 22.

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; University of Chicago Medicine & Biological Sciences, Knapp Center for Biomedical Discovery, Chicago, USA.

Background: In the phase III KEYNOTE-189 study (NCT02578680), pembrolizumab plus pemetrexed and platinum-based chemotherapy (pemetrexed-platinum) significantly improved overall survival (OS) and progression-free survival (PFS) in patients with previously untreated metastatic nonsquamous non-small-cell lung cancer (NSCLC) versus placebo plus pemetrexed-platinum. We report updated efficacy outcomes from the protocol-specified final analysis, including outcomes in patients who crossed over to pembrolizumab from pemetrexed-platinum and in patients who completed 35 cycles (∼2 years) of pembrolizumab.

Patients And Methods: Eligible patients were randomized 2 : 1 to receive pembrolizumab 200 mg (n = 410) or placebo (n = 206) every 3 weeks (for up to 35 cycles, ∼2 years) plus four cycles of pemetrexed (500 mg/m) and investigators' choice of cisplatin (75 mg/m) or carboplatin (area under the curve 5 mg·min/ml) every 3 weeks, followed by pemetrexed until progression. Read More

View Article and Full-Text PDF

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.

Lancet Oncol 2021 05 12;22(5):655-664. Epub 2021 Apr 12.

EORTC Headquarters, Brussels, Belgium.

Background: The European Organisation for Research and Treatment of Cancer (EORTC) 1325-MG/KEYNOTE-054 trial in patients with resected, high-risk stage III melanoma demonstrated improved recurrence-free survival with adjuvant pembrolizumab compared with placebo (hazard ratio 0·57 [98·4% CI 0·43-0·74]; p<0·0001). This study reports the results from the health-related quality-of-life (HRQOL) exploratory endpoint.

Methods: This double-blind, randomised, controlled, phase 3 trial was done at 123 academic centres and community hospitals across 23 countries. Read More

View Article and Full-Text PDF

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.

Lancet Oncol 2021 05 12;22(5):643-654. Epub 2021 Apr 12.

EORTC Headquarters, Brussels, Belgium.

Background: The European Organisation for Research and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial assessed pembrolizumab versus placebo in patients with resected high-risk stage III melanoma. At 15-month median follow-up, pembrolizumab improved recurrence-free survival (hazard ratio [HR] 0·57 [98·4% CI 0·43-0·74], p<0·0001) compared with placebo, leading to its approval in the USA and Europe. This report provides the final results for the secondary efficacy endpoint, distant metastasis-free survival and an update of the recurrence-free survival results. Read More

View Article and Full-Text PDF

Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study.

Lancet Respir Med 2021 06 6;9(6):613-621. Epub 2021 Apr 6.

University of Chicago, Chicago, IL, USA.

Background: Malignant pleural mesothelioma (MPM) has few treatment options. Pembrolizumab showed preliminary clinical benefit in programmed death ligand 1 (PD-L1)-positive MPM. We evaluated the efficacy and safety of pembrolizumab monotherapy in patients with previously treated MPM irrespective of PD-L1 status in the KEYNOTE-158 study. Read More

View Article and Full-Text PDF

Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.

Lancet Oncol 2021 05 1;22(5):665-677. Epub 2021 Apr 1.

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.

Background: In the KEYNOTE-177 study, pembrolizumab monotherapy provided statistically significant and clinically meaningful improvements in progression-free survival versus chemotherapy as first-line treatment in patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer. To further support the efficacy and safety findings of the KEYNOTE-177 study, results of the health-related quality of life (HRQOL) analyses are reported here.

Methods: KEYNOTE-177 is an open-label, randomised, phase 3 trial being done at 192 cancer centres in 23 countries, in patients aged 18 years and older with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer, with an Eastern Cooperative Oncology Group performance status of 0 or 1, and who had not received previous systemic therapy for metastatic disease. Read More

View Article and Full-Text PDF

Proceedings From The 11th Annual University Of Calgary Leaders In Medicine Research Symposium.

Clin Invest Med 2021 03 21;44(1):E42-57. Epub 2021 Mar 21.

Cumming School of Medicine, University of Calgary, Alberta, Canada.

On November 8th, 2019, the Cumming School of Medicine at the University of Calgary hosted the 11th annual Leaders in Medicine (LIM) Research Symposium. Dr. Donald A. Read More

View Article and Full-Text PDF

Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study.

Eur J Cancer 2021 May 12;148:24-35. Epub 2021 Mar 12.

Medical Oncology, Campus Bio-Medico University, Rome, Italy.

Background: Treatment sequencing with first-line immunotherapy, followed by second-line chemotherapy, is still a viable option for NSCLC patients with PD-L1 expression ≥50%.

Methods: We evaluated post-progression treatment pathways in a large real-world cohort of metastatic NSCLC patients with PD-L1 expression ≥ 50% treated with first-line pembrolizumab monotherapy.

Results: Overall, 974 patients were included. Read More

View Article and Full-Text PDF

Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study.

ESMO Open 2021 Apr 12;6(2):100079. Epub 2021 Mar 12.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address:

Background: Preclinical studies suggest that combining vandetanib (VAN), a multi-tyrosine kinase inhibitor of rearranged during transfection (RET) proto-oncogene, vascular endothelial growth factor receptor (VEGFR), and epidermal growth factor receptor (EGFR), with everolimus (EV), a mammalian target of rapamycin (mTOR) inhibitor, may improve antitumor activity. We determined the safety, maximum tolerated dose (MTD), recommended phase II dose (RP2D), and dose-limiting toxicities (DLTs) of VAN + EV in patients with advanced solid cancers and the effect of combination therapy on cancer cell proliferation and intracellular pathways.

Patients And Methods: Patients with refractory solid tumors were enrolled in a phase I dose-escalation trial testing VAN (100-300 mg orally daily) + EV (2. Read More

View Article and Full-Text PDF

Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy.

Ann Oncol 2021 05 17;32(5):590-599. Epub 2021 Feb 17.

Department of Medical Oncology, Hospital Clínico Universitario de Valencia, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain. Electronic address:

Gastroesophageal adenocarcinoma (GEA) and squamous esophageal cancer (ESCC) are responsible for >1 million deaths annually globally. Until now, patients with metastatic GEA and ESCC could anticipate survival of <1 year. Anti- programmed cell death protein 1 (anti-PD-1) monotherapy has demonstrated modest efficacy in previously treated GEA and ESCC. Read More

View Article and Full-Text PDF

The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting October 2019: Impending Change, Innovation, and Future Challenges.

Front Pharmacol 2020 19;11:580560. Epub 2020 Nov 19.

Niche Science & Technology Ltd., Richmond, United Kingdom.

The Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI) annual meeting focused on impending change, innovation, and future challenges facing early phase drug development as we move into the second decade of the 21th century. The meeting opened with discussion around the technical revolution in pharmaceutical medicine over the 4 decades since the AHPPI was founded and how transformative technologies have accompanied the introduction of processes such as physiologically based pharmacokinetic modeling. During the meeting examples were presented of how in terms of the development of new therapies, the classic phases of clinical drug development are becoming a thing of the past and the lines between the phases have begun to blur, particularly in the field of oncology. Read More

View Article and Full-Text PDF
November 2020

Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma.

Eur J Cancer 2021 Feb 24;144:182-191. Epub 2020 Dec 24.

Melanoma Institute Australia, The University of Sydney, 40 Rocklands Rd, Wollstonecraft, NSW, 2065, Australia; Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, 610 University Ave, Toronto, ON, M5G2C1, Canada; The Kinghorn Cancer Centre at St Vincent's Hospital, 370 Victoria St, Darlinghurst, NSW, 2010, Australia; St Vincent's Clinical School, UNSW Sydney, Victoria St, Darlinghurst, NSW, 2010, Australia. Electronic address:

Objective: Long-term safety of pembrolizumab in melanoma was analyzed in KEYNOTE-001, KEYNOTE-002, and KEYNOTE-006.

Patients And Methods: Analysis involved patients who received ≥1 pembrolizumab dose. Lead-time bias was addressed via landmark analyses in patients who were progression-free before day 147. Read More

View Article and Full-Text PDF
February 2021

Interview with Professor Cynthia J. Burrows, 2020 Keynote Speaker, American Chemical Society Division of Chemical Toxicology.

Chem Res Toxicol 2020 12 1;33(12):2915-2916. Epub 2020 Dec 1.

Department of Biochemistry, Vanderbilt University School of Medicine, 638 Robinson Research Building, 2200 Pierce Avenue, Nashville, Tennessee 37232-0146, United States.

View Article and Full-Text PDF
December 2020

Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer.

Ther Adv Med Oncol 2020 20;12:1758835920909091. Epub 2020 Mar 20.

Cross Cancer Institute, Edmonton, Alberta, Canada.

Background: Triple-negative breast cancer (TNBC) represents an aggressive breast cancer subtype with historically poor overall outcomes, due primarily to a lack of effective targeted agents. Chemotherapy has been the primary treatment approach, although immune checkpoint inhibitors (ICIs) are currently being investigated to improve patient outcomes. This review examines the clinical implications of current evidence on the use of ICIs for the treatment of metastatic TNBC. Read More

View Article and Full-Text PDF

Gender Equity at Surgical Conferences: Quantity and Quality.

J Surg Res 2021 02 28;258:100-104. Epub 2020 Sep 28.

University Hospital, Cleveland Medical Center, Surgery at Case Western Reserve University School of Medicine, Director of UH RISES: Research in Surgical Outcomes and Effectiveness Center, President of the Association of Women Surgeons, University Hospitals, Cleveland, Ohio. Electronic address:

Background: Participation of women at national surgery conferences is an important aspect of achieving gender equity; however, participation has to be meaningful and representative of scientific and clinical achievement. We hypothesized that the presence of women on planning committees would increase the number of women speakers and the presence of women as moderators would increase the number of women panelists. Furthermore, we hypothesized that although women may be included as speakers, they are less likely to speak on clinical and technical surgical topics than men. Read More

View Article and Full-Text PDF
February 2021

How media empower the vulnerable: Using community structure theory to analyze relationships between demographics and health reporting.

John C Pollock

Int J Nurs Sci 2020 Sep 30;7(Suppl 1):S16-S18. Epub 2020 May 30.

Depts. of Communication Studies and Public Health, The College of New Jersey, USA.

Instead of studying the impact of media on society, the traditional "top down" orientation of most communication studies scholars, this keynote presentation adopted the opposite perspective, exploring the "bottom-up" impact of "society" on "media". Unlike conventional "agenda-setting theory", which suggests that nationally prominent news media set issue "agendas" for other news media and public opinion, and also unlike the "guard dog" view that media essentially protect the interests of political and economic elites, the "community structure theory" explores links between different community (typically city or nation-state) demographics and variations in reporting on critical health concerns. Summarizing his scholarship on health communication presented and published over decades, the speaker outlined community structure theory's illumination of two overall patterns in US and cross-national coverage of health communication issues. Read More

View Article and Full-Text PDF
September 2020

A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.

Ann Oncol 2020 12 22;31(12):1734-1745. Epub 2020 Sep 22.

University Hospital Zürich, Department of Medical Oncology and Hematology, Zürich, Switzerland. Electronic address:

Background: Malignant pleural mesothelioma (MPM) is an aggressive malignancy characterised by limited treatment options and a poor prognosis. At relapse after platinum-based chemotherapy, single-agent chemotherapy is commonly used and single-arm trials of immune-checkpoint inhibitors have demonstrated encouraging activity.

Patients And Methods: PROMISE-meso is an open-label 1:1 randomised phase III trial investigating the efficacy of pembrolizumab (200 mg/Q3W) versus institutional choice single-agent chemotherapy (gemcitabine or vinorelbine) in relapsed MPM patients with progression after/on previous platinum-based chemotherapy. Read More

View Article and Full-Text PDF
December 2020

Reconsidering ventilator-associated pneumonia from a new dimension of the lung microbiome.

EBioMedicine 2020 Oct 16;60:102995. Epub 2020 Sep 16.

Cellex Laboratory, CibeRes (Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, 06/06/0028), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain; School of Medicine, University of Barcelona, Barcelona, Spain; Department of Pneumology, Thorax Institute, Hospital Clinic of Barcelona, Spain. Electronic address:

Complex microbial communities that reside in the lungs, skin and gut are now appreciated for their role in maintaining organ, tissue and immune homoeostasis. As lungs are currently seen as an ecosystem, the shift in paradigm calls for the consideration of new algorithms related to lung ecology in pulmonology. Evidence of lung microbiota does not solely challenge the traditional physiopathology of ventilator-associated pneumonia (VAP); indeed, it also reinforces the need to include molecular techniques in VAP diagnosis and accelerate the use of immunomodulatory drugs, including corticosteroids, and other supplements such as probiotics for VAP prevention and/or treatment. Read More

View Article and Full-Text PDF
October 2020

Each for Equal: Gender Inequity in Dentistry in Australia.

M Silva L Teoh

JDR Clin Trans Res 2021 Jul 20;6(3):311-316. Epub 2020 Jul 20.

Melbourne Dental School, The University of Melbourne, Victoria, Australia.

Objective: While there is an increasing number of women entering the dental profession, they are still underrepresented in leadership roles in major dental organizations, academia, and journal boards. Keynote and invited speaking roles in professional and scientific conferences recognize expertise and leadership and are key factors in career advancement and academic promotions. The aim of this study was to investigate gender differences in representation at dental continuing professional development (CPD) events and conferences in Australia. Read More

View Article and Full-Text PDF

Health Café Series: a Potential Platform to Reduce Health Disparities.

J Racial Ethn Health Disparities 2020 08 15;7(4):592-594. Epub 2020 Jun 15.

Connecticut Convergence Institute for Translation in Regenerative Engineering, School of Medicine, University of Connecticut Health Center, Farmington, CT, 06030, USA.

To help bridge the increasing gap between health scientists/physicians and the community, we have developed a new seminar program-Health Café series. Health Café takes place in causal settings, is open to everyone, and features a keynote speaker regarding prevalent healthcare-related topics. Health Café topics are usually generated via community feedback and are coordinated in partnership with local nonprofit community organizations. Read More

View Article and Full-Text PDF

Gender Variation in Invited Presenters at Two National Radiology Specialty Meetings.

Curr Probl Diagn Radiol 2021 Jul-Aug;50(4):472-476. Epub 2020 May 16.

Department of Radiology, NYU Langone Health, New York, NY.

Rationale And Objectives: To assess gender balance amongst invited speakers at 2 national radiology conferences over the past decade.

Materials And Methods: The 2009, 2014, and 2019 Association of University Radiologists (AUR) and American Roentgen Ray Society (ARRS) conference programs were evaluated for the number and gender of invited speakers, as well as various presentation characteristics. Gender balance was stratified across conferences and years. Read More

View Article and Full-Text PDF

Highlights of the 3rd ISCB Africa Student Council Symposium 2019 in Ghana.

F1000Res 2020 27;9. Epub 2020 May 27.

Bioinformatics and Computational Biology Program, Iowa State University, Ames, Iowa, USA.

The article elaborates on the program highlights of the 3rd African Student Council Symposium 2019. The one-day symposium was held in Kwame Nkrumah University of Science and Technology (KNUST), Ghana, on 11 November 2019 during the 6th joint international bioinformatics conference of the ISCB and ASBCB. It consisted of three sessions that included keynote talks by Prof Christine Orengo and Dr. Read More

View Article and Full-Text PDF

Adjuvant immunotherapy: the sting in the tail.

Eur J Cancer 2020 06 5;132:207-210. Epub 2020 May 5.

Institute of Cancer Sciences, University of Manchester and the Christie NHS Foundation Trust, Manchester, UK. Electronic address:

Adjuvant therapy with PD-1 inhibitors for resected Stage III/IV melanoma reduces the risk of recurrence by 40-50% and is now a standard of care. Immune-related adverse events occurred in approximately 37% of patients in the pivotal trials, 10-15% were severe (grade III-IV). Endocrine toxicities were common and mostly irreversible. Read More

View Article and Full-Text PDF